Osteoporosis in pituitary diseases: lessons for the clinic

References

• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-25
   PubMed Web of Science ®Google Scholar
• Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002;77(5):453-68
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Canalis A. Growth hormone, insulin like growth factor and the skeleton. Endocr Rev 2008;29(5):535-59
   PubMed Web of Science ®Google Scholar
• Ueland T, Fougner SL, Godang K, et al. Serum GH and IGF-1 are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol 2006;155(5):709-15
   PubMed Web of Science ®Google Scholar
• Ernst M, Froesch ER. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor-1. Biochem Biophys Res Commun 1988;151(1):142-7
   PubMedGoogle Scholar
• Padova G, Borzi GL, Incorvaia L, et al. Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab 2011;8(3):37-43
   PubMedGoogle Scholar
• Bolanowski M, Daroszewski J, Mędraś M, et al. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity and gonadal function. J Bone Miner Metab 2006;24(1):72-8
   PubMed Web of Science ®Google Scholar
• Madeira M, Neto LV, Torres CH, et al. Vertebral fracture assessment in acromegaly. J Clin Densitom 2013;16(2):238-43
   PubMed Web of Science ®Google Scholar
• Lesse GP, Fraser WD, Farquharson R, et al. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf) 1998;48(1):59-65
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013;98(8):3402-10
   PubMed Web of Science ®Google Scholar
• Bolanowski M, Jędrzejuk D, Milewicz A, et al. Quantitative ultrasound of the heel and some parameters of bone turnover in patients with acromegaly. Osteoporos Int 2002;13:303-8
   PubMed Web of Science ®Google Scholar
• Kaji H, Sugimoto T, Nakaoka D, et al. Bone metabolism and body composition in Japanese patients with active aromegaly. Clin Endocrinol (Oxf) 2001;55(2):175-81
   PubMedGoogle Scholar
• Ohlsson C, Bengtsson BA, Isaksson OG, et al. Growth hormone and bone. Endocr Rev 1998;19(1):55-79
   PubMed Web of Science ®Google Scholar
• Katznelson L, Kleinbeg D, Vance ML, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 2001;54(2):183-8
   PubMedGoogle Scholar
• Diamond T, Nery L, Posen S. Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. Ann Intern Med 1989;111(7):567-73
   PubMedGoogle Scholar
• Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008;93(12):4649-55
   PubMed Web of Science ®Google Scholar
• Madeira M, Neto LV, de Paula Paranhos Neto F, et al. Acromegaly has a negative influence on trabecular bone but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2013;98(4):1734-41
   PubMedGoogle Scholar
• Bolanowski M, Pluskiewicz W, Adamczyk P, et al. Quantitative ultrasound at the hand phalanges in patients with acromegaly. Ultrasound Med Biol 2006;32(2):191-5
   PubMedGoogle Scholar
• Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005;20(10):1837-44
   PubMed Web of Science ®Google Scholar
• Wassenaar MJ, Biermasz NR, Hamdy NAT, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 2011;164(4):475-83
   PubMed Web of Science ®Google Scholar
• Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 1997;12:1729-36
   PubMedGoogle Scholar
• Parkinson C, Kassem M, Heickendorff M, et al. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 2003;88:5650-5
   PubMed Web of Science ®Google Scholar
• Kamenicky P, Mazziotti G, Lombes M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiology and clinical implications. Endocr Rev 2014;35:234-81
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65(2):265-73
   PubMed Web of Science ®Google Scholar
• Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983;56(6):1120-3
   PubMedGoogle Scholar
• Mazziotti G, Porceli T, Mormando M, et al. Vertebral fractures in males with prolactinoma. Endocrine 2011;39(3):288-93
   PubMed Web of Science ®Google Scholar
• Seriwatanachai D, Thongchote K, Charoenphandhu N, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008;42(3):535-46
   PubMed Web of Science ®Google Scholar
• Klibanski A, Biller BM, Rosenthal DI, et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67(1):124-30
   PubMedGoogle Scholar
• Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women with hyperprolactinemia. J Clin Endocrinol Metab 1992;75(3):698-703
   PubMedGoogle Scholar
• Matsuyama J, Eshima N, Fukunaga T, et al. Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab 2003;21(2):91-7
   PubMedGoogle Scholar
• Miller KK, Klibanski A. Clinical review 106: amenorrheic bone loss. J Clin Endocrinol Metab 1999;84(6):1775-83
   PubMedGoogle Scholar
• Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83(3):807-13
   PubMedGoogle Scholar
• Naliato EC, Farias ML, Braucks GR, et al. Prevalence of osteopenia in men with prolactinoma. Endocrinol Invest 2005;28(1):12-17
   PubMed Web of Science ®Google Scholar
• Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amennorhea. N Engl J Med 1986;315(9):542-6
   PubMedGoogle Scholar
• Greenspan SL, Neer RM, Ridgway EC, et al. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986;104(6):777-82
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Jørgensen JO, Hagan C, et al. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. Clin Endocrinol (Oxf) 2002;56(2):159-67
   PubMedGoogle Scholar
• Zadrożna-Śliwka B, Bolanowski M, Kałużny M, et al. Bone mineral density and bone turnover in hyperprolactinaemia of various origins. Endokrynol Pol 2007;58(2):116-22
   PubMedGoogle Scholar
• Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 5-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996;135(5):548-52
   PubMedGoogle Scholar
• Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bulletin Johns Hopkins Hospital 1932;50:137-95
   Google Scholar
• Kaltsas G, Makras P. Skeletal disease in Cushing’s syndrome: osteoporosis versus arthropathy. Neuroendocrinology 2010;92(1):60-4
   PubMedGoogle Scholar
• Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006;17(4):144-9
   PubMed Web of Science ®Google Scholar
• Chiodini I, Torlontano M, Carnevale V, et al. Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 2008;31(3):267-76
   PubMed Web of Science ®Google Scholar
• van der Eerden AW, den Heijer M, Oyen WJ, et al. Cushing’s syndrome and bone mineral density: lowest Z scores in young patients. Neth J Med 2007;65(4):137-41
   PubMedGoogle Scholar
• Dekkers OM, Horváth-Puhó E, Jørgensen JOL, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013;98(6):2277-84
   PubMed Web of Science ®Google Scholar
• Lekva T, Ueland T, Bøyum H, et al. TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing’s syndrome and related to bone turnover. Eur J Endocrinol 2012;166(6):1039-48
   PubMedGoogle Scholar
• Mancini T, Doga M, Mazziotti G, et al. Cushing’s syndrome and bone. Pituitary 2004;7(4):249-52
   PubMedGoogle Scholar
• Rizzoli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2012;91(4):225-43
   PubMedGoogle Scholar
• Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 2010;163(1):15-20
   PubMed Web of Science ®Google Scholar
• Wüster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001;16(2):398-405
   PubMed Web of Science ®Google Scholar
• Holmer H, Svensson J, Rylander L, et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res 2007;22(12):1842-50
   PubMedGoogle Scholar
• Degerblad M, Bengtsson BA, Bramnert M, et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 1995;133(2):180-8
   PubMedGoogle Scholar
• Toogood AA, Adams JE, O’Neill PA, et al. Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997;82(5):1462-6
   PubMedGoogle Scholar
• Tritos NA, Greenspan SL, King D, et al. Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis. J Clin Endocrinol Metab 2011;96(5):1516-23
   PubMedGoogle Scholar
• Gómez JM, Gómez N, Fiter J, et al. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Horm Metab Res 2000;32(2):66-70
   PubMedGoogle Scholar
• Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999;84(6):1919-24
   PubMed Web of Science ®Google Scholar
• Högler W, Shaw N. Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol (Oxf) 2010;72(3):281-9
   PubMed Web of Science ®Google Scholar
• Filipsson H, Johannsson G. GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 2009;161(Suppl 1):S85-95
   Google Scholar
• Richelson LS, Wahner HW, Melton LJ3rd, et al. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311(20):1273-5
   PubMed Web of Science ®Google Scholar
• Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology and prevention. Medicine 1990;69(3):137-52
   PubMed Web of Science ®Google Scholar
• Wolinsky-Friedland M. Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 1995;24(2):395-420
   PubMedGoogle Scholar
• Kaufman JM, Taelman P, Vermeulen A, et al. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. Clin Endocrinol Metab 1991;74(1):118-23
   Google Scholar
• de Boer H, Blok GJ, van Lingen A, et al. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9:1319-26
   PubMed Web of Science ®Google Scholar
• Wüster C. Growth hormone and bone. Acta Endocrinol 1993;128(suppl 2):14-18
   PubMedGoogle Scholar
• Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 2014;99(3):852-60
   PubMedGoogle Scholar
• Rota F, Savanelli MC, Tauchmanova L, et al. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest 2008;31(2):94-102
   PubMedGoogle Scholar
• Kann P, Piepkorn B, Schehler B, et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf) 1998;48(5):561-8
   PubMedGoogle Scholar
• Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 2006;21(4):520-8
   PubMedGoogle Scholar
• Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol 2014;170(6):893-9
   PubMed Web of Science ®Google Scholar
• Abe E, Marians RC, Yu W, et al. TSH Is a Negative Regulator of Skeletal Remodeling. Cell 2003;115(2):151-62
   PubMed Web of Science ®Google Scholar
• Colaianni G, Cuscito C, Colucci S. FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis. Clin Dev Immunol 2013;2013:382698
   PubMedGoogle Scholar
• Agrawal M, Zhu G, Sun L, et al. The role of FSH and TSH in bone loss and its clinical relevance. Curr Osteoporos Rep 2010;8(4):205-11
   PubMedGoogle Scholar
• Xu Z-R, Wang A-H, Wu X-P, et al. Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women. Clin Chim Acta 2009;400(1-2):8-13
   PubMed Web of Science ®Google Scholar
• Sowers MR, Finkelstein JS, Ettinger B, et al. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN. Osteoporos Int 2003;14(1):44-52
   PubMed Web of Science ®Google Scholar